SCHEMBL4890853

SCHEMBL4890853

CCc1ccc(-n2cc(C(=O)O)c(=O)c3cnc(Nc4ccc5cn[nH]c5c4)nc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 18/20 0.52
FLT3 P36888 5/20 0.49
DAPK3 O43293 2/20 0.49
PRKD3 O94806 2/20 0.49
MAP4K4 O95819 2/20 0.49
PAK4 O96013 2/20 0.49
PIM1 P11309 2/20 0.49
PRKACA P17612 2/20 0.49
CDK2 P24941 2/20 0.49
SYK P43405 2/20 0.49
CSNK1A1 P48729 2/20 0.49
CLK2 P49760 2/20 0.49
CDK9 P50750 2/20 0.49
JAK3 P52333 2/20 0.49
CDK5 Q00535 2/20 0.49
MAP4K2 Q12851 2/20 0.49
STK3 Q13188 2/20 0.49
DYRK1A Q13627 2/20 0.49
PKN2 Q16513 2/20 0.49
HIPK2 Q9H2X6 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4590311 0.90 CSF1R (0.65) CSF1RFLT3KITSRCNTRK1
SCHEMBL4889908 0.83 CSF1R (0.54) CSF1RFLT3KITSRCNTRK1
SCHEMBL4893976 0.81 CSF1R (0.57) CSF1RFLT3KITSRCNTRK1
SCHEMBL4891418 0.81 CSF1R (0.56) CSF1RFLT3KITSRCNTRK1
SCHEMBL4888703 0.80 CSF1R (0.52) CSF1RFLT3KITSRCNTRK1
SCHEMBL4892291 0.80 CSF1R (0.55) CSF1RFLT3KITSRCNTRK1
SCHEMBL4573128 0.80 CSF1R (0.69) CSF1RFLT3KITSRCNTRK1
SCHEMBL4881803 0.79 CSF1R (0.54) CSF1RFLT3KITSRCNTRK1
SCHEMBL4589368 0.79 CSF1R (0.68) CSF1RFLT3KITSRCNTRK1
SCHEMBL4891857 0.79 CSF1R (0.57) CSF1RFLT3KITSRCNTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114007-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114007-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE FLT3, FES, ALK CSF1R 430/4885FLT3 1/4885DAPK3 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.